The Device (DND) Replaces Tuning Forks and Monofilaments...

Kazu Suzuki DPM, Medical Director of the Tower Wound Care Center at the Cedars-Sinai Medical Towers in Los Angeles, CA; Managing Neuropathy And Pain In Wound Care Patients, Podiatry Today; September 2015; 26-27.

PAD is Underdiagnosed in 75% of Patients Who Exhibit No Symptoms...

Sillisen H, Falk E: Peripheral Arterial Disease (PAD) Detection, Awareness, and Treatment in Primary Care, JAMA 2001: Vol 286: 1317-1324

Lower-Extremities

The Diabetes Testing Centers™ has a comprehensive combination of assessments for lower extremities with the TruPAD™ and the Diabetic Neuropathy Device™ presents many benefits for patients with diabetes. By employing these cutting-edge devices, medical professionals can conduct thorough and precise evaluations of peripheral artery function and neuropathic conditions. This comprehensive approach allows for early detection of potential issues, enabling timely intervention and personalized care plans. The utilization of TruPAD™ facilitates non-invasive vascular assessments, providing valuable insights into blood flow and circulation in the lower extremities. Simultaneously, the Diabetic Neuropathy Device™ offers detailed neuropathy testing, evaluating sensory functions and identifying abnormalities. Together, these devices contribute to a holistic understanding of a patient's vascular and neuropathic health, empowering healthcare providers to tailor interventions that mitigate the risk of complications, enhance overall well-being, and foster a proactive approach to diabetes management.

The TruPAD™ solution offers a rapid, straightforward, and precise method for measuring the Ankle Brachial Index (ABI), which is crucial in identifying Peripheral Artery Disease (PAD), which often goes undiagnosed in 66% of cases, remaining symptomless. PAD reduces blood flow to the feet and legs, causing pain and potential complications like tissue death (gangrene). Individuals with diabetes and a history of smoking are at the highest risk. Studies indicate that at least 1 in 5 older adults suffer from hardened arteries, reducing blood flow to the limbs. The TruPAD™ Rapid-Test System accurately detects PAD in-office, providing comprehensive reports within seconds, benefiting early detection and treatment. By simplifying testing, TruPAD™ enhances patient outcomes and offers financial advantages through reimbursement opportunities. Its cost-effectiveness and portability make it an ideal choice for medical clinics with multiple sites, particularly in cases involving diabetic patients and calcified or incompressible arteries.

(Painful) Diabetic Small Fiber Neuropathy can Only be Verified with Thermal Thresholds or Skin Biopsies.

Aaron Vinik, MD, Ph.D., Endocrinologist, Diabetic Neuropathies, February 5, 2018 

Diabetic Neuropathy Device™ (DND) is the first FDA Cleared multi-objective tool that identifies/verifies and measures large and small nerve fibers in upper and lower extremities. The Diabetic Neuropathy Device™ (inv. 2014) significantly improves over traditional tools for detecting and measuring neuropathy in diabetic patients. Clinical studies have shown that the DND provides more accurate results than tuning forks and monofilaments, often offering false-positive and false-negative test results. With the DND, medical providers can standardize diabetic foot exams across the United States, leading to better patient outcomes. With the DND, medical providers can accurately diagnose and monitor diabetic neuropathy, leading to better treatment and improved patient outcomes. Its effectiveness has been hailed as the most significant innovation in diabetic neuropathy over the past 80 years, making it an essential tool for medical professionals, and is eligible for reimbursements from Medicare, Medicaid, and commercial payers. 

(Painless) Diabetic Large Nerve Fiber Dysfunction as Measured by Vibration Predicts Foot Ulceration, Amputation and Mortality.

https://care.diabetesjournals.org/content/32/10/1896